ERBB2 and adenocarcinoma: Moreover, it is recruiting in five clinical studies and completed seven studies in conditions including metastatic breast cancer, HER2 gene mutation, adenocarcinoma lung stage IV, advanced solid malignancies, HER2+ advanced gastric cancer, increased drug resistance and advanced solid tumor.